• Explore /
  • Poster
  • / Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.

Abstract Poster

Authors

null

Paul Swiecicki

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI

Paul Swiecicki , Emrullah Yilmaz , Ari J. Rosenberg , Takao Fujisawa , Justine Yang Bruce , Changting Meng , Michele Wozniak , Lu Wang , Seema Rao Gorla , Jessica Lyn Geiger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04225117

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6017)

DOI

10.1200/JCO.2023.41.16_suppl.6017

Abstract #

6017

Poster Bd #

9

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.

First Author: Kei Muro

First Author: John Raymond Zalcberg

First Author: Zhen Zeng

First Author: Robin Lewis Jones